{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:02:54Z","timestamp":1789603374046,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.apsb.2026.07.027","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:36:10Z","timestamp":1784356570000},"page":"6030-6044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elesclomol-mediated cuproptosis overcomes cisplatin resistance by restricting epigenetically activated mitochondrial respiration: Novel therapeutic insights into cisplatin\u2013elesclomol combination therapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Tianyu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengsen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renbing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.07.027_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2026.07.027_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101041","article-title":"Metastatic uveal melanoma: the final frontier","volume":"90","author":"Rantala","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.apsb.2026.07.027_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.07.027_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.apsb.2026.07.027_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajo.2011.03.004","article-title":"Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival","volume":"152","author":"Augsburger","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apsb.2026.07.027_bib6","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.07.027_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CMR.0000000000000401","article-title":"Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study","volume":"27","author":"Schinzari","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.apsb.2026.07.027_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"Homsi","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.apsb.2026.07.027_bib9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0959-8049(03)00132-1","article-title":"Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma","volume":"39","author":"Kivel\u00e4","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.apsb.2026.07.027_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41420-022-00949-y","article-title":"JMJD2C mediates the MDM2\/p53\/IL5RA axis to promote CDDP resistance in uveal melanoma","volume":"8","author":"Zhu","year":"2022","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.apsb.2026.07.027_bib11","first-page":"405","article-title":"Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin","volume":"26","author":"B\u00e9rub\u00e9","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2026.07.027_bib12","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/s41467-022-32101-w","article-title":"Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells","volume":"13","author":"Tan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.07.027_bib13","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2022.11.014","article-title":"Dysregulated amino acid sensing drives colorectal cancer growth and metabolic reprogramming leading to chemoresistance","volume":"164","author":"Solanki","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2026.07.027_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccell.2017.06.004","article-title":"MUC1 and HIF-1\u03b1 signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.07.027_bib15","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-22-3059","article-title":"Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer","volume":"83","author":"Lin","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.07.027_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/0008-5472.CAN-22-2045","article-title":"Enhanced glutaminolysis drives hypoxia-induced chemoresistance in pancreatic cancer","volume":"83","author":"Park","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.07.027_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s44178-024-00096-7","article-title":"Oncometabolites in cancer: from cancer cells to the tumor microenvironment","volume":"3","author":"Chen","year":"2024","journal-title":"Holist Integr Oncol"},{"key":"10.1016\/j.apsb.2026.07.027_bib18","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.07.027_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41416-019-0658-4","article-title":"MFN1-dependent alteration of mitochondrial dynamics drives hepatocellular carcinoma metastasis by glucose metabolic reprogramming","volume":"122","author":"Zhang","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.07.027_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155615","article-title":"Targeting the dynamics of cancer metabolism in the era of precision oncology","volume":"145","author":"Zheng","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.apsb.2026.07.027_bib21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cell.2023.11.022","article-title":"Metabolic regulation of homologous recombination repair by MRE11 lactylation","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.07.027_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2017.09.009","article-title":"MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation","volume":"26","author":"Lee","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2026.07.027_bib23","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s00277-023-05203-8","article-title":"MYC-targeted genes predict distant recurrence in patients with ocular adnexal extranodal marginal zone lymphoma","volume":"102","author":"Zhu","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.apsb.2026.07.027_bib24","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1093\/nar\/gkad1193","article-title":"Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A","volume":"52","author":"Gu","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.07.027_bib25","article-title":"Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma","volume":"4","author":"Xing","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.apsb.2026.07.027_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2023.125168","article-title":"Global LC\u2013MS\/MS targeted metabolomics using a combination of HILIC and RP LC separation modes on an organic monolithic column based on 1-vinyl-1,2,4-triazole","volume":"267","author":"Basov","year":"2024","journal-title":"Talanta"},{"key":"10.1016\/j.apsb.2026.07.027_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12915-024-01927-9","article-title":"ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner","volume":"22","author":"Zhu","year":"2024","journal-title":"BMC Biol"},{"key":"10.1016\/j.apsb.2026.07.027_bib28","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/cac2.12471","article-title":"Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m6A RNA methylation in ocular melanoma","volume":"43","author":"Zhuang","year":"2023","journal-title":"Cancer Commun"},{"key":"10.1016\/j.apsb.2026.07.027_bib29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.apsb.2023.12.002","article-title":"EHMT2 promotes tumorigenesis in GNAQ\/11-mutant uveal melanoma via ARHGAP29-mediated RhoA pathway","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.07.027_bib30","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1038\/s41388-022-02364-0","article-title":"Copper ionophore elesclomol selectively targets GNAQ\/11-mutant uveal melanoma","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.07.027_bib31","article-title":"Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia","volume":"7","author":"Chen","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.07.027_bib32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.abf0529","article-title":"Copper induces cell death by targeting lipoylated TCA cycle proteins","volume":"375","author":"Tsvetkov","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.07.027_bib33","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41418-023-01125-0","article-title":"Cuproptosis: p53-regulated metabolic cell death?.","volume":"30","author":"Xiong","year":"2023","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.apsb.2026.07.027_bib34","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.07.027_bib35","article-title":"A cancerous web: signaling, metabolism, and the epigenome","volume":"2","author":"Lee","year":"2015","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.apsb.2026.07.027_bib36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2015.05.014","article-title":"Acetyl coenzyme A: a central metabolite and second messenger","volume":"21","author":"Pietrocola","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2026.07.027_bib37","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2012-01-401687","article-title":"Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia","volume":"119","author":"Bhatla","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.07.027_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13148-023-01615-5","article-title":"Histone acetylation: a key determinant of acquired cisplatin resistance in cancer","volume":"16","author":"Natu","year":"2024","journal-title":"Clin Epigenet"},{"key":"10.1016\/j.apsb.2026.07.027_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113629","article-title":"Metabolic reprogramming by histone deacetylase inhibition preferentially targets NRF2-activated tumors","volume":"43","author":"Karagiannis","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.07.027_bib40","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1038\/s41467-021-25260-9","article-title":"SMARCA4\/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria","volume":"12","author":"Xue","year":"2021","journal-title":"Nat Commun"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:16:24Z","timestamp":1789600584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526004661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2211383526004661"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.07.027","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elesclomol-mediated cuproptosis overcomes cisplatin resistance by restricting epigenetically activated mitochondrial respiration: Novel therapeutic insights into cisplatin\u2013elesclomol combination therapy","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}